R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The new capital is expected to fund the company through 2029
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Subscribe To Our Newsletter & Stay Updated
